Trioxacarcin Antibody Drug Conjugates for Targeted DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) rely on a limited spectrum of cytotoxic agents, leading to treatment susceptibility to resistance and inadequate addressing of cancer cell sensitivities across various tumor types.
Innovation Solution
Development of trioxacarcin analogs and their incorporation into ADC constructs, leveraging a unique trimodal binding pattern of intercalation, alkylation, and base flip-out for enhanced DNA complexation, along with a favorable safety profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a limited spectrum of cytotoxic agents is used in ADCs, then the development process is simpler and more manageable, but treatment susceptibility to resistance increases and cancer cell sensitivities across various tumor types are not adequately addressed
Solution Approach 1:
The patent modifies the chemical structure of trioxacarcin compounds by introducing various substituents (R1-R6 groups) to create analogs with different properties. This allows tuning of the cytotoxic agent's characteristics to match different cancer cell sensitivities while maintaining the core mechanism of action, thereby addressing diverse tumor types without requiring completely different ADC constructs
Solution Approach 2:
The patent combines trioxacarcin analogs with antibody components to create composite ADC structures. The trioxacarcin core maintains its unique trimodal binding pattern (intercalation, alkylation, and base flip-out) while the antibody portion provides target specificity, creating a composite system that leverages both components' strengths to address multiple cancer cell sensitivities
2Power
If highly potent cytotoxic agents like trioxacarcin are used in ADCs, then potency against cancer cells increases, but toxicity and side effects increase
Solution Approach 1:
The patent introduces specific substituent patterns (R1-R6 groups) at different positions of the trioxacarcin core structure. These local modifications allow optimization of the cytotoxic region's potency while the overall molecular architecture controls the distribution and metabolism of the agent, thereby reducing systemic toxicity. The unique trimodal binding pattern is preserved in the high-potency regions while toxic effects are mitigated through structural refinement
Solution Approach 2:
The antibody component serves as an intermediary that delivers the trioxacarcin analog specifically to cancer cells expressing the target antigen. This targeted delivery mechanism ensures that the highly potent cytotoxic agent acts primarily at the disease site rather than systemically, thereby maintaining high potency against cancer cells while reducing overall toxicity and side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of trioxacarcin analogs in ADCs provides a diversified arsenal of cytotoxic agents, potentially increasing specificity and potency against cancer cells while reducing toxicity and side effects.
Implementation Method 1
the trioxacarcins' trimodal binding pattern-intercalation, alkylation, and base flip-out-is a unique mechanism for DNA complexation
Implementation Method 2
the trioxacarcins' trimodal binding pattern-intercalation, alkylation, and base flip-out-is a unique mechanism for DNA complexation
Data Source
AI summary
Provided herein are compound of Formula (I) and (II), and pharmaceutically acceptable salts thereof. Also provided are methods of preparing the compounds, pharmaceutically acceptable compositions thereof, and methods of their use and treatment.